Cash Flow Statement
The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.
The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.
Paying user area
Try for free
Abiomed Inc. pages available for free this week:
- Statement of Comprehensive Income
- Analysis of Long-term (Investment) Activity Ratios
- Common Stock Valuation Ratios
- Enterprise Value to FCFF (EV/FCFF)
- Capital Asset Pricing Model (CAPM)
- Dividend Discount Model (DDM)
- Net Profit Margin since 2005
- Operating Profit Margin since 2005
- Debt to Equity since 2005
- Price to Book Value (P/BV) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Abiomed Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Abiomed Inc., consolidated cash flow statement
US$ in thousands
Based on: 10-K (reporting date: 2022-03-31), 10-K (reporting date: 2021-03-31), 10-K (reporting date: 2020-03-31), 10-K (reporting date: 2019-03-31), 10-K (reporting date: 2018-03-31), 10-K (reporting date: 2017-03-31).
- Net Income
- Net income showed an overall upward trend from 2017 to 2021, increasing from approximately $52.1 million to $225.5 million. However, in 2022, net income declined sharply to $136.5 million, representing a notable decrease compared to the previous year.
- Depreciation and Amortization
- This expense increased steadily each year from $6.2 million in 2017 to $28.1 million in 2022, indicating ongoing investments in fixed assets and possibly intangible assets.
- Acquired In-Process Research & Development
- An item appearing only in 2022 at $116.0 million suggests a significant acquisition or investment in research and development during that year.
- Stock-Based Compensation Expense
- This expense exhibited a generally increasing trend from $32.9 million in 2017 to $52.7 million in 2022, reflecting growing employee compensation through stock options or awards.
- Write-down of Inventory and Other
- Write-downs increased substantially over the period, from $3.1 million in 2017 to $18.0 million in 2022, suggesting increasing inventory obsolescence or valuation adjustments.
- Accretion on Marketable Securities
- This non-cash income fluctuated, showing negative figures in 2019 and 2020 but positive gains in 2021 and 2022 ($1.98 million and $3.7 million respectively), indicating variability in investment yields or valuation changes.
- Change in Fair Value of Investments
- The item showed volatility with a large negative change in 2019 (-$30.2 million), positive change in 2020 ($5.2 million), followed by significant negative changes in 2021 (-$51.0 million) and 2022 (-$22.9 million), highlighting fluctuating investment performance or impairments.
- Deferred Tax Provision
- The deferred tax provision was positive and relatively high in the early years, peaking in 2020 at $32.9 million, but substantially declined to $2.4 million in 2022, indicating changes in tax liabilities or asset valuations.
- Changes in Working Capital (Assets and Liabilities)
- Changes were largely negative in most years except 2020 which showed a positive $8.0 million change, with notable decreases in accounts receivable and inventories particularly in 2019 and 2022. This suggests fluctuating operational asset management.
- Net Cash Provided by Operating Activities
- Operating cash flow increased steadily from $115.1 million in 2017 to a peak of $314.9 million in 2020 before declining slightly in 2021 and increasing again to $285.4 million in 2022, demonstrating strong cash-generating ability throughout the period.
- Investing Activities
- Significant cash outflows for investing activities increased notably in 2022 (-$381.0 million), substantially higher than in previous years. Large purchases of marketable securities and acquisitions (e.g., preCARDIA, Breethe) were key contributors. Proceeds from sales and maturity of marketable securities also increased, but not sufficiently to offset purchases.
- Financing Activities
- Financing cash flow was generally negative or slightly positive, with notable outflows in 2020 (-$117.7 million). Activities included payments related to stock awards, repurchases of common stock, and proceeds from stock option exercises and employee stock purchases, indicating active capital structure management.
- Cash and Cash Equivalents
- Cash increased considerably between 2017 and 2021, peaking at $232.7 million before dropping to $132.8 million in 2022. The decline in 2022 corresponds with significant investing outflows and reduced net income, reflecting the financial strategies and operational results of that year.